

15 October 2015

## **Appointment of Non-Executive Director**

The Board of Directors of Antisense Therapeutics Limited ('ANP' or the 'Company') is pleased to announce the appointment of Mr. William Goolsbee as a Non-Executive Director of the Company.

Mr. Goolsbee brings a wealth of experience to the ANP Board having enjoyed a 30 year career in the medical device and biopharmaceutical industries. He has been on the Board of US NASDAQ Healthcare company, Sarepta Therapeutics Inc. since 2007 including as Chairman from 2010 to 2014 and has led and supported the company through a significant period of growth (market cap US\$1.4B). Sarepta are developing RNA based therapeutics with their lead program in Duchenne Muscular Dystrophy. Mr. Goolsbee has extensive experience in drug development and commercialisation especially in the Orphan drug/RNA therapeutics space. He also has strong connections with US capital markets and potential strategic investors and partners.

Mr. Goolsbee was founder, Chairman and Chief Executive Officer of Horizon Medical Inc. from 1987 until its acquisition by a unit of UBS Private Equity in 2002. Mr. Goolsbee was a founding Director of ImmunoTherapy Corporation in 1993, and became Chairman in 1995, a position he held until overseeing the successful acquisition of ImmunoTherapy by AVI Biopharma, Inc. (now Sarepta Therapeutics) in 1998. Mr. Goolsbee served as Chairman of privately held BMG Pharma LLC, a pharmaceutical company, from 2006 through 2011 and of Metrodora Therapeutics until 2015.

Mr. Goolsbee holds a B.A. degree from the University of California at Santa Barbara.

In welcoming Mr. Goolsbee to the Board, Antisense Therapeutics Chairman Bob Moses said "I am extremely pleased that Bill has agreed to join our Board and I am confident he will provide significant practical, as well as strategic value to the Company. Bill's extensive experience in various aspects of the biopharmaceutical industry is highly relevant to our Company, particularly with respect to assisting us to increase the value of the Company for our shareholders. He has been involved with drug development programs in therapeutics similar to ours and he has experience in the entire regulatory process required for drug development and approval. Bill has also overseen many successful corporate initiatives including M&A. Bill is a perfect fit for our Company".

Mr. Goolsbee will replace outgoing non-executive Director, Dr Chris Belyea who had previously advised his intent not to stand for re-election at the 12 November 2015 Annual General Meeting and to retire from the ANP Board at the conclusion of the AGM. Dr Belyea's industry knowledge and scientific and commercial insights have been greatly valued and the Company thanks Dr Belyea for his contribution to the Board and Company.

Mr. Goolsbee added "I am delighted to be appointed to the Board of Antisense Therapeutics. It's an exciting time at ANP with the progress being made on the development of their drug platform which is attracting global pharmaceutical interest. I am looking forward to working with the Board and assisting Mark Diamond and his team to capitalise on the many opportunities that they have been progressing. Having two Phase II drugs places them in a unique position going forward."

Mr. Goolsbee's appointment is effective immediately and will be confirmed after the 2015 Annual General Meeting.

*Contact Information:*

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director – Mark Diamond +61 3 9827 8999